Key facts
- Gyala Therapeutics’s last known valuation is $21.8M (Sep 2025).
- It has raised $6.2M; the latest was Later Stage VC ($3.5M) in Sep 2025.
- Notable investors include INNVIERTE SICC, Invivo Partners, Nara Capital AM.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Gyala Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Gyala Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gyala Therapeutics
Developer of cancer therapeutics designed to treat hematological malignancies. The company's therapeutics include a gene therapy that involves modifying the patient's own lymphocytes, a type of white blood cells responsible for immune response, enabling clients in the medical community and patients to combat leukemia and other critical diseases.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2020
- Employees
- 8
- Website
- gyalatx.com/
- Ownership
- Privately Held (backing)
Gyala Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gyala Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gyala Therapeutics in its N-PORT filings yet. We sweep new filings monthly.